Tolerance of normal human brain to boron neutron capture therapy

J A Coderre; J W Hopewell; J C Turcotte; K J Riley; P J Binns; W S Kiger 3rd; O K Harling

doi:10.1016/j.apradiso.2004.05.009

Tolerance of normal human brain to boron neutron capture therapy

Appl Radiat Isot. 2004 Nov;61(5):1083-7. doi: 10.1016/j.apradiso.2004.05.009.

Authors

J A Coderre¹, J W Hopewell, J C Turcotte, K J Riley, P J Binns, W S Kiger 3rd, O K Harling

Affiliation

¹ Nuclear Engineering Department, Massachusetts Institute of Technology, 150 Albany Street, Cambridge, MA 02139, USA. coderre@mit.edu

PMID: 15308196
DOI: 10.1016/j.apradiso.2004.05.009

Abstract

Data from the Harvard-MIT and the BNL Phase I and Phase I/II clinical trials, conducted between 1994 and 1999, have been analyzed and combined, providing the most complete data set yet available on the tolerance of the normal human brain to BPA-mediated boron neutron capture therapy. Both peak (1cm(3)) dose and average whole-brain dose show a steep dose-response relationship using somnolence syndrome as the clinical endpoint. Probit analysis indicates that the doses associated with a 50% incidence for somnolence (ED(50)+/-SE) were 6.2+/-1.0 Gy(w) for average whole-brain dose and 14.1+/-1.8 Gy(w) for peak brain dose.

Publication types

Clinical Trial
Clinical Trial, Phase I
Clinical Trial, Phase II
Research Support, Non-U.S. Gov't

MeSH terms

Boron Compounds / therapeutic use
Boron Neutron Capture Therapy / adverse effects*
Brain / radiation effects*
Brain Neoplasms / radiotherapy
Disorders of Excessive Somnolence / etiology
Glioblastoma / radiotherapy
Humans
Melanoma / radiotherapy
Phenylalanine / analogs & derivatives*
Phenylalanine / therapeutic use
Radiation Tolerance

Substances

4-dihydroxyborylphenylalanine
Boron Compounds
Phenylalanine